Literature DB >> 30916385

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.

David M Ross1,2,3,4, Ilaria S Pagani2,4, Yazad D Irani2, Jade Clarson1,2, Tamara Leclercq2, Phuong Dang2, Jennifer McLean2, Verity A Saunders2, Lisa Carne1, John Reynolds5, David S Ritchie6,7, Deborah L White2, Susan Branford3,8,9, Timothy P Hughes1,2,3,4, Agnes S M Yong2,4.   

Abstract

Entities:  

Keywords:  chronic myeloid leukaemia; immunology; minimal residual disease; treatment-free remission

Mesh：

Substances：

Year:  2019        PMID： 30916385     DOI： 10.1111/bjh.15894

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Treatment-free remission and immunity in chronic myeloid leukemia.

Authors:  Hiroshi Ureshino
Journal:  Int J Hematol       Date:  2021-03-02       Impact factor: 2.490

Review 2.  Treatment-free remission in patients with chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Nat Rev Clin Oncol       Date:  2020-05-06       Impact factor: 66.675

Review 3.  Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.

Authors:  Ya-Ching Hsieh; Kristina Kirschner; Mhairi Copland
Journal:  Leukemia       Date:  2021-04-08       Impact factor: 12.883

Review 4.  Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.

Authors:  Richard E Clark
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 5.  Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.

Authors:  Ruth Stuckey; Juan Francisco López Rodríguez; María Teresa Gómez-Casares
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.